Home > Core technology > Universal Off-the-Shelf in vivo CAR-T Cell Therapy Technology
The company's proprietary universal off-the-shelf in vivo CAR-T technology requires no lymphodepletion, no ex vivo expansion or genetic engineering of T cells, greatly simplifying the manufacturing process. The technology offers strong cell fitness/stemness, prolonged in vivo persistence, enhanced targeting specificity, and improved precision and safety. Through standardized vector manufacturing and preparation, costs are significantly reduced, yielding substantial commercial value.